Evofem Biosciences Enters Material Definitive Agreement
Ticker: EVFM · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1618835
Sentiment: neutral
Topics: material-definitive-agreement, corporate-update
TL;DR
Evofem just signed a big deal, filing shows.
AI Summary
Evofem Biosciences, Inc. announced on October 13, 2025, that it has entered into a material definitive agreement. The company, formerly known as Neothetics, Inc., is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates a significant new contract or partnership for Evofem Biosciences, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can carry inherent risks related to the terms, execution, and potential impact on the company's financial health.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- Neothetics, Inc. (company) — Former company name
- October 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Evofem Biosciences?
The filing does not specify the details of the material definitive agreement, only that one has been entered into on October 13, 2025.
When was Evofem Biosciences previously known as?
Evofem Biosciences, Inc. was formerly known as Neothetics, Inc., with a name change date of September 5, 2014.
Where are Evofem Biosciences' principal executive offices located?
The principal executive offices of Evofem Biosciences, Inc. are located at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
What is the Commission File Number for Evofem Biosciences?
The Commission File Number for Evofem Biosciences, Inc. is 001-36754.
What is the SIC code for Evofem Biosciences?
The Standard Industrial Classification (SIC) code for Evofem Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-10-17 16:05:44
Filing Documents
- form8-k.htm (8-K) — 35KB
- ex10-1.htm (EX-10.1) — 30KB
- 0001493152-25-018454.txt ( ) — 226KB
- evfm-20251013.xsd (EX-101.SCH) — 3KB
- evfm-20251013_lab.xml (EX-101.LAB) — 33KB
- evfm-20251013_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Third Amendment to Securities Purchase Agreement dated as of October 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Dated: October 17, 2025 By: /s/ Saundra Pelletier Saundra Pelletier Chief Executive Officer